口服诺如病毒疫苗在2b期安慰剂对照攻毒研究中诱导黏膜免疫并减少病毒排出
目前尚无获批的诺如病毒疫苗,2期研究向3期现场试验推进缺乏可靠的免疫保护相关性指标。本研究开展2b期随机安慰剂对照疫苗接种与攻毒试验,评估口服片剂诺如病毒疫苗VXA-G1.1-NN的安全性、有效性、免疫原性和保护相关性。结果显示该疫苗安全耐受,可抵御诺如病毒GI.1攻毒,减少粪便和呕吐物中的病毒排出;接种后血清VP1特异性IgA、IgG和功能性阻断抗体滴度大幅升高,鼻黏膜液、唾液和粪便中亦诱导VP1特异性IgA;机器学习分析识别出血清功能性阻断抗体和粪便IgA为稳健的保护相关性指标。
要点
- VXA-G1.1-NN口服疫苗安全且耐受良好,可抵御诺如病毒GI.1攻毒。
- 疫苗接种减少粪便和呕吐物中的病毒排出。
- 血清功能性阻断抗体和粪便IgA被识别为稳健的保护相关性指标。
核心结论
- VXA-G1.1-NN有望成为安全有效的口服诺如病毒疫苗,并揭示了支撑疫苗效力的关键免疫学特征。
研究设计与样本
- 2b期随机安慰剂对照疫苗接种与攻毒研究,评估口服片剂诺如病毒疫苗VXA-G1.1-NN的安全性、有效性、免疫原性和保护相关性。
主要发现
- VXA-G1.1-NN安全且耐受良好,可抵御诺如病毒GI.1攻毒,并减少粪便和呕吐物中的病毒排出。
- 口服疫苗接种后,诺如病毒VP1特异性血清免疫球蛋白A(IgA)、IgG和功能性阻断抗体滴度大幅升高。
- 口服免疫在鼻黏膜液、唾液和粪便样本中刺激产生VP1特异性IgA抗体。
- 疫苗接种后7天的血清和黏膜抗体反应与抗体分泌型α4β7+黏膜归巢B细胞的诱导相关。
- 对疫苗刺激的免疫组分进行机器学习分析,识别出血清功能性阻断抗体和粪便IgA为稳健的保护相关性指标。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are currently no licensed vaccines for norovirus, a leading cause of epidemic and endemic gastroenteritis worldwide. Clinical advancement of promising vaccine candidates from phase 2 studies to phase 3 field trials has been hampered by the lack of robust immunological correlates of protection. Here, we conducted a phase 2b randomized, placebo-controlled vaccination and challenge study to assess the safety, efficacy, immunogenicity, and correlates of protection of VXA-G1.1-NN, an oral tablet norovirus vaccine. VXA-G1.1-NN was safe and well tolerated, conferred protection against norovirus GI.1 challenge, and reduced viral shedding in stool and emesis. Norovirus VP1-specific serum immunoglobulin A (IgA), IgG, and functional blocking antibody titers increased substantially after oral vaccination. Moreover, oral immunization stimulated VP1-specific IgA antibodies in nasal lining fluid, saliva, and fecal samples. Serum and mucosal antibody responses 7 days after vaccination were correlated with the induction of antibody-secreting, α4β7+ mucosal-homing B cells. Machine learning analyses of vaccine-stimulated immune components identified serum functional blocking antibody and fecal IgA as robust correlates of protection. These results demonstrate the potential of VXA-G1.1-NN as a safe and effective oral norovirus vaccine and reveal critical immunological features underpinning vaccine efficacy.
引用
- Flitter BA, Gillard J, Greco SN, et al. An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study. Sci Transl Med. 2025. PMID: 40367195. doi:10.1126/scitranslmed.adh9906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。